Frequently Asked Questions

Questions for Patients and Caregivers

When will the IpsiHand be available?

The IpsiHand will be available for potential candidates at select locations throughout the US this year.  Make sure you are on our mailing list to receive updates about our location for trialing the device.

 

How much does the IpsiHand cost?

We have several purchase plans based on your needs. Make sure you are on our mailing list to receive further information.

 

Does insurance cover the IpsiHand?

Since IpsiHand is a new, breakthrough technology, there is not yet established insurance coverage.  We will assist you to submit your claim for the IpsiHand System if that is of interest to you.

 

I had a brain injury, can I use the IpsiHand?

Currently this IpsiHand is indicated for chronic stroke survivors  with upper limb weakness due to stroke.

 

I have a child who had a stroke. Can they use the IpsiHand?

Currently the IpsiHand is indicated for use in adults age 18 and older, as the IpsiHand has not been studied in the pediatric population.

 

Are there any clinical trials I can participate in?

We plan to launch future clinical trials. Make sure you are on our mailing list to receive updates about our clinical trials.

 

Do I have to be seeing an occupational therapist or physical therapist to qualify to use the IpsiHand?

No, we can work with your clinician if you are currently enrolled in a rehabilitation therapy program. In addition, our Clinical Team consists of experienced  Occupational Therapists with advanced certifications to provide you assistance and information for screening and set-up of the IpsiHand System.

How long would I need to use the IpsiHand to see potential results?

One hundred percent of clinical trial participants saw improvement of their arm and/or hand function following participation in the study. Our clinical trials demonstrated clinically significant arm and hand improvement for 66.7% of trial participants. The IpsiHand study protocols required use of the device approximately 1 hour per day, 5 to 7 days a week for a total of at least 12 weeks in patients 6 or more months post-stroke. Participants in our clinical trials used the IpsiHand system at home for the duration of the study. 

 

Questions for Healthcare Professionals and Clinical Sites

Which patient diagnoses qualify to use the IpsiHand?

Currently, the IpsiHand is indicated for chronic stroke survivors 18 years and older with upper limb weakness due to stroke.

How much active movement is necessary to use the IpsiHand?

No active movement is necessary to use the IpsiHand System due to the brain-based control mechanism, however, full passive movement of the elbow, wrist and digits is recommended to comfortably wear the device.

How can I schedule an inservice about the IpsiHand at my clinic?

If you’re interested in more information about inservices at your facility or being an early adopter clinical site, make sure you’ve filled out our contact form. We’re working on a webinar introduction to BCI course for clinicians that we will have available in 2022 for CE credit. Check back next year for more information.

I have a patient who is interested in using the IpsiHand. What should I do next?

We are planning to release a commercial version of the IpsiHand device in 2022 in limited quantities. The IpsiHand will be available for potential candidates at select locations throughout the US this year.  Join the waitlist to be the first to know about available devices.

How long would a patient need to use the IpsiHand to have the potential to see results?

Subjects across our clinical studies utilized the IpsiHand for  1 hour per day,  5 to days a week for a total of 12 weeks in those who were 6 or more months post-stroke. Subjects in our clinical trials used the IpsiHand system at home for the total duration of the study.  Across all clinical studies, 100% of the subjects demonstrated improvement on the primary outcome measure. A total of 66.7% of these subjects exceeded the minimal clinical important difference (MCID). The MCID is the smallest change in a treatment outcome that an individual patient would identify as an important improvement.